IMV102 treatment
Phase 1
IMV102 treatment is one of 14 therapeutic programs targeting Relapsed/Refractory Multiple Myeloma. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
13
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
16 competitors in Relapsed/refractory Multiple Myeloma
#DrugCompanyPhaseTrials
1Decadron
AAspen Global Incorporated
Phase 3
Pomalyst
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Elranatamab
PfizerPhase 3
Darzalex
Johnson & JohnsonPhase 1
Revlimid
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 1
Etentamig
AbbViePhase 1
Kyprolis
VVirionyx Corporation Limited
Preclinical
Beqalzi
BBeOne Medicines
Preclinical
AZD0120
AstraZenecaPreclinical
Linvoseltamab
RegeneronPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for IMV102 treatment. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 1[1]